Prestige Consumer Healthcare (PBH) Income from Continuing Operations (2010 - 2025)
Prestige Consumer Healthcare (PBH) posted quarterly Income from Continuing Operations of 46696000.0 for Q4 2025, down 23.49% year-over-year from 61032000.0 in Q4 2024, and up 10.63% quarter-over-quarter from 42211000.0 in Q3 2025.
Prestige Consumer Healthcare (PBH) Income from Continuing Operations (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 46696000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 23.49% year-over-year to 46696000.0; the TTM figure through Dec 2025 stood at 186501000.0 (down 12.82% YoY), while the FY2025 annual figure was 214605000.0, up 2.52% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 46696000.0, up from 42211000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 61032000.0 in Q4 2024, with the low at 240552000.0 in Q1 2023.
- The 5-year median for Income from Continuing Operations is 50619000.0 (2021), against an average of 35945300.0.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 561.84% in 2023, then surged 120.56% in 2024.
- Prestige Consumer Healthcare's Income from Continuing Operations stood at 50215000.0 in 2021, then grew by 3.46% to 51951000.0 in 2022, then climbed by 2.11% to 53046000.0 in 2023, then climbed by 15.05% to 61032000.0 in 2024, then slipped by 23.49% to 46696000.0 in 2025.
- Business Quant data shows PBH's Income from Continuing Operations at 46696000.0 in Q4 2025, 42211000.0 in Q3 2025, and 47466000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Prestige Consumer Healthcare | 2.44 Bn | 2.38 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46.70 Mn |
| Sep 30, 2025 | 42.21 Mn |
| Jun 30, 2025 | 47.47 Mn |
| Mar 31, 2025 | 50.13 Mn |
| Dec 31, 2024 | 61.03 Mn |
| Sep 30, 2024 | 54.38 Mn |
| Jun 30, 2024 | 49.07 Mn |
| Mar 31, 2024 | 49.46 Mn |
| Dec 31, 2023 | 53.05 Mn |
| Sep 30, 2023 | 53.56 Mn |
| Jun 30, 2023 | 53.28 Mn |
| Mar 31, 2023 | -240.55 Mn |
| Dec 31, 2022 | 51.95 Mn |
| Sep 30, 2022 | 51.02 Mn |
| Jun 30, 2022 | 55.27 Mn |
| Mar 31, 2022 | 52.09 Mn |
| Dec 31, 2021 | 50.22 Mn |
| Sep 30, 2021 | 45.33 Mn |
| Jun 30, 2021 | 57.76 Mn |
| Mar 31, 2021 | 35.51 Mn |